Hypothesis: How do JAK2-inhibitors work in myelofibrosis

Leukemia Research

Volumn 33, Issue 9, 2009, Pages 1156-1157

  Mesa, Ruben ^b   Gale, Robert Peter ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b MAYO CLINIC   (United States)

Author keywords

JAK2; JAK2 inhibitors; Myelofibrosis; Myeloproliferative disorders; Myeloproliferative neoplasms

Indexed keywords

JANUS KINASE 2; JANUS KINASE 2 INHIBITOR; JANUS KINASE INHIBITOR; UNCLASSIFIED DRUG;

ALLELE; ANEMIA; ARTICLE; CLINICAL TRIAL; DRUG MECHANISM; DRUG RESPONSE; GENE MUTATION; HEMATOPOIESIS; HOMOZYGOSITY; HUMAN; LEUKEMIA; LEUKEMOGENESIS; LEUKOCYTE; MYELOFIBROSIS; PRIORITY JOURNAL; SPLENOMEGALY; SYMPTOM; THROMBOCYTE;

EID: 67549114832     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.04.011     Document Type: Note

References (6)

1. James C., Ugo V., Le Couedic J.P., Staerk J., Delhommeau F., Lacout C., et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434 (2005) 1144-1148
2. Pardanani A. JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials. Leukemia 22 (2008) 23-30
3. Pardanani A.D., Gotlib J., Jamieson C., Cortes J., Talpaz M., Stone R.M., et al. A phase I study of TG101348, an orally bioavailable JAK2-selective inhibitor, in patients with myelofibrosis. Blood 112 (2008) 97
4. Verstovsek S., Kantarjian H.M., Pardanani A.D., Thomas D., Cortes J., Mesa R.A., et al. The JAK inhibitor, INCB018424, demonstrates durable and marked clinical responses in primary myelofibrosis (PMYELOFIBROSIS) and post-polycythemia/essential thrombocythemia myelofibrosis (post PV/ETMYELOFIBROSIS). ASH annual meeting abstracts, vol. 112 (2008) 1762
5. Rambaldi A., Dellacasa C.M., Salmoiraghi S., Spinelli O., Ferrari M.L., Gattoni E., et al. A phase 2A study of the histone-deacetylase inhibitor ITF2357 in patients with Jak2V617F positive chronic myeloproliferative neoplasms. Blood 112 (2008) 100
6. Mesa R.A., Li C.Y., Schroeder G., and Tefferi A. Clinical correlates of splenic histopathology and splenic karyotype in myelofibrosis with myeloid metaplasia. Blood 97 (2001) 3665-3667